Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic
  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

InvestorNewsBreaks — IGC Pharma Inc. (NYSE American: IGC) Enters into $3M SPA with Leading Asset Management Company

IGC Pharma (NYSE American: IGC), a clinical-stage pharmaceutical company, has received a $3 million strategic investment from funds managed by Bradbury Asset Management (Hong Kong) Limited, a leading asset management company. According to the announcement, IGC Pharma entered into a share purchase agreement (“SPA”) with Bradbury comprised of IGC issuing 8,823,529 shares of unregistered common stock that are not immediately tradable. The company anticipates using the funds from the agreement for general corporate purposes as well as the development of its investigational medicines, including IGC-AD1. IGC Pharma noted that the completion of the investment is dependent on customary closing conditions, including approval by the NYSE. Under the terms of the SPA, IGC will issue 8,823,529 shares of common stock. The shares are unregistered and are not immediately tradable.

To view the full press release, visit https://ibn.fm/kr3gZ

About IGC Pharma

IGC Pharma is focused on Alzheimer’s disease, developing innovative solutions to address this devastating illness. The company’s mission is to transform the landscape of Alzheimer’s treatment with a robust pipeline of five promising drug candidates. IGC-AD1 and LMP target the hallmarks of Alzheimer’s disease, including neuroinflammation, Aβ plaques, and neurofibrillary tangles. IGC-AD1 is currently undergoing a phase 2 clinical trial for agitation in dementia associated with Alzheimer’s. TGR-63 disrupts the progression of Alzheimer’s by targeting Aβ plaques. IGC-M3, currently in preclinical development, aims to inhibit the aggregation of Aβ plaques, potentially impacting early-stage Alzheimer’s. IGC-1C, also in preclinical stages, targets tau protein and neurofibrillary tangles, representing a forward-thinking approach to Alzheimer’s therapy. In addition to its drug-development pipeline, IGC Pharma seeks to leverage Artificial Intelligence (AI) for Alzheimer’s research. The company’s AI projects encompass various areas, including clinical trial optimization and early detection of Alzheimer’s. For more information, visit the company’s website at www.IGCInc.us.

NOTE TO INVESTORS: The latest news and updates relating to IGC are available in the company’s newsroom at https://ibn.fm/IGC

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.